Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 13/20 | 0.61 |
| ▸ | PIK3CD known ✓ | O00329 | 7/20 | 0.61 |
| ▸ | PIK3CB known ✓ | P42338 | 6/20 | 0.61 |
| ▸ | PIK3CG known ✓ | P48736 | 6/20 | 0.61 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.45 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 15/20 | 0.61 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.61 |
| ▸ | FECH | P22830 | 1/20 | 0.61 |
| ▸ | CLK1 | P49759 | 1/20 | 0.61 |
| ▸ | GSK3A | P49840 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
| ▸ | MELK | Q14680 | 1/20 | 0.61 |
| ▸ | MYLK3 | Q32MK0 | 1/20 | 0.61 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.61 |
| ▸ | TP53RK | Q96S44 | 1/20 | 0.61 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.55 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905022 | 1.00 | MTOR (0.61) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9905060 | 0.95 | MTOR (0.66) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9905112 | 0.90 | PIK3CA (0.48) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9905117 | 0.90 | PIK3CA (0.48) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9905167 | 0.88 | MTOR (0.56) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9905380 | 0.86 | MTOR (0.64) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9905106 | 0.85 | PIK3CA (0.55) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9905281 | 0.85 | PIK3CA (0.52) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL9905279 | 0.83 | PIK3CA (0.51) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL2068184 | 0.83 | MTOR (0.58) | MTORPIK3CAPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | PIRAMAL ENTERPRISES LIMITED` (IN) | 2013-11-21 | — | — | US | claimed |
| EP-2648733-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2013-10-16 | — | — | EP | claimed |
| WO-2012077031-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-06-14 | — | — | WO | claimed |
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | PIRAMAL ENTERPRISES LIMITED` (IN) | 2013-11-21 | — | — | US | disclosed |
| EP-2648733-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2013-10-16 | — | — | EP | disclosed |
| WO-2012077031-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310374-A1 | Substituted Imidazoquinoline Derivatives | FLT4, CDK4, CDK2 | PIK3CA 154/4885PIK3CD 262/4885PIK3CB 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.